Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209790 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemoradiation for Resectable Glioblastoma
A Phase 2 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04209790: Clinical Trial Phase 2 study, sponsored by Geisinger Clinic.
NCT04209790 is a Phase 2 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04209790, a Phase 2 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This Phase II study design would be used to proceed with the study treatment after meeting pre-specified events in the initial phase, with goal being to determine whether the new treatment paradigm is sufficiently promising to warrant a major controlled clinical evaluation against the standard therapy.
Primary Outcome
Number of participants with no study related undue toxicity or progression within the limits of stage one patients. Toxicity is defined as: progression precluding surgery, unanticipated neurological decompensation, non-completion of neoadjuvant therapy (other than protocol defined dose adjustments or discontinuation), treatment related delay of \>6 weeks to surgery, and/or major unforeseen surgical complication requiring repeat surgical intervention including other than non-life-threatening infe
Interventions
- RADIATION Neoadjuvant chemoradiation
- DRUG Drug Therapy with Temozolomide (benzolamide) (Standard of Care)
- PROCEDURE Surgery post Radiation and Temozolomide (benzolamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 2 |
Why NCT04209790 stopped before completion
NCT04209790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Neoadjuvant chemoradiation is the first listed.
NCT04209790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04209790 about?
NCT04209790 is a clinical study titled "Neoadjuvant Chemoradiation for Resectable Glioblastoma". Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This...
What is the current status of trial NCT04209790?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-04-01. Estimated completion is 2022-09-14.
What interventions are being tested in trial NCT04209790?
The interventions under investigation include: Neoadjuvant chemoradiation (RADIATION), Drug Therapy with Temozolomide (benzolamide) (Standard of Care) (DRUG), Surgery post Radiation and Temozolomide (benzolamide) (PROCEDURE).
Who is sponsoring clinical trial NCT04209790?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04209790's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI